Don Griffin is an expert in hydrogel-based biomaterials for tissue engineering, regenerative medicine, and drug delivery. He is also an inventor of the microporous annealed particle (MAP) technology that is commercialized by Tempo Therapeutics and is one of the foremost global experts in the properties and potential of the MAP platform technology. Dr. Griffin is a co-founder of Tempo Therapeutics and is the company’s Chief Science Officer (CSO). As the company CSO, he has helped to secure over $3M in federal funding and build a growing patent portfolio. Dr. Griffin is also an assistant professor of Biomedical Engineering at the University of Virginia where he maintains a National Institute of Health (NIH) supported research group that continues to explore both the basic properties and translational potential of MAP.